PAR
Click for more information
2.17% 23.5¢ paradigm biopharmaceuticals limited..

research reports and media, page-117

  1. Gan_Gans
    2,130 Posts.
    lightbulb Created with Sketch. 569
    clock Created with Sketch.
    19/09/19
    21:35
    Post #: 40486916
    Paradigmers: thoughts on Gilead’s drug acquired from Galapagos currently in P2 trials?

    https://clinicaltrials.gov/ct2/show/NCT03595618
    PAR Price at posting: $2.10 Sentiment: Buy Disclosure: Held
    Likes Created with Sketch. 1  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
right-arrow Created with Sketch.
RLT South Africa-based Renergen brings liquid helium facility online
right-arrow Created with Sketch.
BOE Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan
right-arrow Created with Sketch.
TG6 TG Metals reports high grade lithium hits approaching 3% at Jaegermeister
right-arrow Created with Sketch.
MGU Collaboration in a green (steel) future the focus for Magnum and Saudi partners
right-arrow Created with Sketch.
NEWS Bitcoin: Current State of Play & Where to Next | Swyftx
right-arrow Created with Sketch.
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
23.5¢ 		Change
0.005(2.17%) 		Mkt cap ! $82.20M
Open High Low Value Volume
24.0¢ 25.0¢ 23.0¢ $101.6K 424.7K

Buyers (Bids)

No. Vol. Price($)
12 144266 23.0¢
 

Sellers (Offers)

Price($) Vol. No.
24.5¢ 18540 1
View Market Depth
Last trade - 16.10pm 09/08/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.